ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Total Liabilities: HK$340.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
6 GF Score
Price HK$3.66
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) Total Liabilities?

ImmuneOnco Biopharmaceuticals (Shanghai) HKSE:01541 +4.57% 6 Total Liabilities is HK$340.5 Mil as of Dec. 2025. GuruFocus rates HKSE:01541 with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities for the quarter that ended in Dec. 2025 was HK$340.5 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly Total Liabilities declined from Dec. 2024 (HK$260.18 Mil) to Jun. 2025 (HK$259.45 Mil) but then increased from Jun. 2025 (HK$259.45 Mil) to Dec. 2025 (HK$340.55 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual Total Liabilities increased from Dec. 2023 (HK$138.15 Mil) to Dec. 2024 (HK$260.18 Mil) and increased from Dec. 2024 (HK$260.18 Mil) to Dec. 2025 (HK$340.55 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Total Liabilities Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Total Liabilities Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
3,050.48 67.85 138.15 260.18 340.55

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only 138.15 153.98 260.18 259.45 340.55
HKSE:01541
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=304.425+(36.125+-0.0010000000000332
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=340.5

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1213.43-872.881
=340.5

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=304.425+(36.125+-0.0010000000000332
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=340.5

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1213.43-872.881
=340.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$340.5 Mil mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a Total Liabilities of HK$340.5 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Total Liabilities is HK$340.5 Mil. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Liabilities of HK$340.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Total Liabilities is HK$340.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current Total Liabilities of HK$340.5 Mil. The current Total Liabilities is HK$340.5 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current Total Liabilities is HK$340.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for HKSE:01541

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.66
Price